Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new treatments ...

Biogen raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures ...

Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

The drugmaker will bring on Bristol Myers Squibb exec Daniel Quirk as chief medical officer and head of medical affairs, a ...

Biogen (NASDAQ: BIIB) Q3 2024 Earnings Call Oct 30, 2024, 8:30 a.m. ET ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare ...

Biogen (BIIB) announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, ...